Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $24M million Series C financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners.